Loading clinical trials...
Loading clinical trials...
This study will monitor the long-term effects of gene therapy in patients with severe combined immunodeficiency disease (SCID) due to a deficiency in an enzyme called adenosine deaminase (ADA). It wil...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
National Human Genome Research Institute (NHGRI)
NCT01306019 · X-linked Severe Combined Immunodeficiency (XSCID)
NCT06659588 · Humoral Primary Immunodeficiencies (PIDs), Secondary Form of Humoral Immunodeficiencies, and more
NCT04049084 · Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency (SCID)
NCT01852370 · Severe Combined Immunodeficiency (SCID), Immunodeficiency With Predominant T-cell Defect, Unspecified, and more
NCT06731036 · Severe Combined Immunodeficiency, Fanconi Anemia, and more
National Human Genome Research Institute (NHGRI)
Bethesda, Maryland
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions